Abstract
Introduction
Uveal melanoma is the most common primary intraocular neoplasm in adults, with an annual incidence of six to eight per million in Caucasian populations (Egan et al., 1988) . In contrast to cutaneous melanoma, clustering of uveal melanoma in families is extremely rare (Van Hees et al., 1998; Kodjikian et al., 2003; Smith et al., 2007) . Occurrence of both uveal melanoma and cutaneous melanoma in a single family has been observed (van Hees et al., 1998) . Recently, Jönsson et al. (Jönsson et al., 2005 ) revealed a genetic component in three such families, in which members are affected by either uveal or cutaneous melanoma. Linkage analysis in these families identified a potential uveal melanoma susceptibility locus on chromosome 9, area q21. This locus has a long history in melanoma that started with detection of isochromosome 9q with cytogenetic analysis (Kopf et al., 1992; Albino et al., 1992) . Loss of heterozygosity (LOH) of markers at 9q22 was subsequently frequently reported and was shown to be associated with proliferation and tumor progression (Boni et al, 1998; Kumar et al., 1999) .
Recently, single nucleotide polymorphism (SNP) analysis has confirmed the LOH of this locus in melanoma, while genome-wide analysis in dizygotic twins for nevi numbers also showed linkage with this 9q region (Zhu et al., 2007; Stark et al., 2007) . In addition, a gene slightly distal to RASEF, RMI1, has recently been shown to be a risk factor for cutaneous melanoma, whereas the locus for familial melanoma susceptibility is located on the short arm of chromosome 9 (Cannon-Albright et al., 1992; Boni et al., 1998; Broberg et al., 2007) . Cutaneous melanomas are often characterized by loss of the cell-cycle regulator p16 and/or activation of the RAS-RAF-ERK pathway (Cohen et al., 2002; Satyamoorthy et al., 2003) . These hallmarks of melanoma are also recognized in uveal melanoma, although the underlying mechanisms differ (Weber et al., 2003; Calipel et al., 2006) . Whereas in cutaneous melanoma, p16 is commonly lost by chromosomal deletion of the CDKN2A gene, the preferential mechanism in uveal melanoma appears to be silencing of the p16-encoding CDKN2A promoter by methylation (van der Velden et al., 2001 ).
Mutations in BRAF, NRAS, or c-kit lead to constitutive ERK activation in most cutaneous melanomas (van Elsas et al., 1996; Davies et al., 2002) . However, mutations in BRAF have only rarely been reported in uveal melanoma, whereas activating NRAS and c-kit mutations have never been reported (Zuidervaart et al., 2005) . Still, ERK activation is also present in uveal melanoma, and this knowledge leads to the question of what causes ERK activation in the absence of activating mutations in BRAF, NRAS, or c-kit (Weber et al., 2003; Zuidervaart et al., 2005; Calipel et al., 2006) .
The RASEF (RAS and EF hand domain containing) gene is located on chromosome 9, area q21, and encodes a protein with calcium-binding EF-hand and Ras GTPase (Rab family) motifs (http://www.genome.ucsc.
edu/ provided in the public domain by the Genome Bioinformatics Group, University of Santa Cruz, CA); it is also known as RAB45 or FLJ31614.22 (Sweetser et al., 2005) . Based on the functional domains in RASEF, the gene product may be engaged in the RAS pathway and in combination with evidence for linkage of the RASEF region with cutaneous and uveal melanoma, molecular analysis of this gene is warranted.
In line with the analysis of cutaneous melanoma reported by Jönsson et al., (Jönsson et al., 2005) we therefore set out to analyze RASEF for mutations and for expression of the gene in uveal melanoma.
Materials and methods

Cell Lines and Primary Uveal Melanoma Specimens
In total, 11 cell lines derived from primary uveal melanomas (92.1; and uveal melanoma metastases (OMM-1, -2.3, and -2.5) were analyzed. All melanoma cell lines were cultured in RPMI 1640 medium (Invitrogen-Gibco, Paisley, Scotland, UK) supplemented with 3 mM L-glutamine (Invitrogen-Gibco), 2% penicillin streptomycin, and 10% FBS (Hyclone, Logan, UT). All cell cultures were incubated at 37°C in a humidified 5% CO2 atmosphere. Archival frozen tumor specimens of primary uveal melanoma came from 35 patients who attended the Leiden University Medical Center between 1988 and 1996. All tumors were primary lesions with a tumor diameter greater than 12 mm, a prominence greater than 6 mm, and no treatment before enucleation. The validity of the diagnosis of uveal melanoma was confirmed histologically in all cases, and clinical and survival data were listed for use in the study ( 
DNA and RNA Extraction and Sodium-Bisulfite Modification
Using a column-based extraction kit (Genomic tip 100/G; Qiagen Benelux BV, Venlo, The Netherlands), DNA was extracted from the cell lines and frozen tumor material, according to the manufacturer's guidelines. RNA was also extracted with a column-based extraction kit (RNeasy mini kit; Qiagen Benelux) from tumors in which enough frozen material was available (n=16). RNA was converted to cDNA (iScript cDNA synthesis kit; Bio-Rad Laboratories BV, Veenendaal, the Netherlands), according to the manufacturer's guidelines. Genomic DNA was modified with sodium bisulfite (EZ Methylation Gold kit; Zymo Research Corp., Orange, CA). Enzymatically methylated human DNA (Chemicon Europe Ltd., Hampshire, UK) was used as the positive control in all experiments. DNA and RNA concentrations were determined by spectrophotometer (model ND-1000; NanoDrop Technologies Inc., Wilmington, DE).
Mutation Screening and Genotyping
A 96-well light scanner (Idaho Technologies Inc., Salt Lake City, UT) for high-resolution melting-curve analysis was used to scan all amplicons of the RASEF gene. The primers are shown in Table 4 .2. DNA samples were amplified with a double-stranded DNA-binding dye (LC Green Plus; Idaho Technologies).
Melting curves were analyzed in plots showing differences in fluorescence. The shift and curve shapes of melting profiles were used to distinguish between samples from control subjects and patients. PCR reaction with the green dye contained PCR buffer (Invitrogen, Breda, The Netherlands), 1.5 mM MgCl 2 , 40 μM dNTPs, 1:10 diluted green dye, 0.4 mM of forward and reverse primers, and 1 unit Taq polymerase per 10-μL reaction (Fast Start; Roche Diagnostics BV, Almere, The Netherlands). PCR consisted of an initial denaturation at 94°C for 6 minutes followed by 40 cycles consisting of 15 seconds at 96°C, 30 seconds at 58°C, and 60 seconds at 72°C, and the PCR ended with a 1-minute denaturation at 94°C. After amplification, the amplified fragments (exon 5) were digested using 4 units of the restriction enzyme BstU1 (New England Biolabs, Beverly, MA) directly added to the PCR mixture. Analysis was performed by overnight digestion of the amplified fragments at 60°C. The BstU1 enzyme recognizes and cleaves the 5'-CG^CG-3' sequence. PCR products were separated on a 2% agarose gel in 1x TBE (0.09 M Tris-borate, 0.002 M EDTA; pH 8.2).
RASEF Expression
The expression of RASEF in 16 tumors for which RNA was available was analyzed with real-time RT-PCR and specific primers, which are shown in Table 4 .2. PCR was performed as described earlier (Maat et al., 2007) . 
Methylation Analysis
We applied bisulfite modification of tumor DNA in combination with PCR, as this introduces sequence differences between methylated and unmethylated DNA that can be analyzed with several methods.
The sequence differences were initially determined with melting-temperature analysis, as this method gov/ a genome database hosted by the National Center for Biotechnology Information, Bethesda, MD).
The primers are shown in Table 4 .2. PCR was performed exactly as described earlier (Maat et al., 2007) .
Melting-Temperature Analysis
A melting-temperature analysis was performed as described earlier (Maat et al., 2007) 
Restriction Digestion Analysis and Sequence Analysis
After amplification with specific primers for bisulfite-converted DNA, the PCR-amplified fragments were digested with 4 units of restriction enzyme HinfI (Fermentas GmbH, St. Leon Rot, Germany) directly added to the PCR mixture (under conditions specified by the manufacturer). The HinfI enzyme recognizes and cleaves the 5'-G^ANTC-3' sequence. This sequence is not present in unmodified DNA and in modified unmethylated DNA. The RASEF amplicon of methylated DNA contains one HinfI recognition site and is dependent on both CT conversion and methylation of a CpG. The recognition site 5'-G^ANTC-3' appears only when the first C in the 5'-GANCC-3' sequence is converted into thymine, whereas the second must be methylated and remains a cytosine. PCR products were separated on a 2% agarose gel in 1x TBE (0.09 M Tris-borate, 0.002 M EDTA; pH 8.2). DNA bands were excised from the gel, purified using a gel extraction kit (Nucleospin Extract II; Macherey-Nagel, GmbH, Düren, Germany) and sequenced (Prism 3700 DNA sequencing system; Applied Biosystems, Foster City, CA).
Pyrophosphorolysis-Activated Polymerization
In the pyrophosphorolysis-activated polymerization (PAP) reaction, primers are used that contain a dideoxy-nucleotide (ddNTP) at their 3' terminus and hence will not be extended. A polymerase with Pyrophosphorolysis activity can remove the dideoxy-cytosine and thereby activate polymerization.
Since this pyrophosphorolysis activity is dependent on double-stranded DNA, only primers that perfectly match the template will be activated. The specificity of Pyrophosphorolysis allows us to amplify specifically the minute amounts of methylated RASEF DNA in the background of unmethylated DNA.
The PAP products can be further validated with sequence analysis for internal CpGs. The primers are shown in Table 4 .2. The amplification was performed in a final volume of 25 mL containing 5 mL 5x PAP buffer (prepared as described by Liu and Sommer), 0.3 mL (10 picomoles/mL) of each primer, 0.5 mL Taq polymerase (KlenTaq; DNA Polymerase Technology, Inc., St. Louis, MO), 17.9 mL H2O, and 1 mL DNA sample . Amplification was initiated by hot start, followed by 40 cycles at 94°C for 15 seconds, 60°C for 40 seconds, 64°C for 40 seconds (T-anneal); 68°C for 40 seconds (pyrophosphorolysis activity); and 72°C for 40 seconds (elongation), and using a final melting curve from 70°C to 97°C with an increase in temperature of 0.2°C every 10 seconds. PCR products were separated on a 2% agarose gel in 1x TBE (0.09 M Tris-borate, 0.002 M EDTA; pH 8.2).
Statistical Analysis
Survival analysis for RASEF promoter methylation was performed using a Kaplan Meier analysis and log rank test (SPSS ver. 14.0 for Windows; SPSS Inc., Chicago, IL). For a comparison between the presence and absence of RASEF methylation and metastatic disease and tumor characteristics, the X 2 test and analysis of variance were performed.
Chapter 4 Results
Mutation Screening in Uveal Melanoma
To analyze RASEF as a tumor-suppressor gene (TSG) candidate, we first investigated the gene for mutations. Mutation screening was performed in two steps: first, the 17 exons were prescreened by high-resolution melting-curve analysis. Though melting-curve analysis showed few variations, we nevertheless generated sequences for 2 tumor samples of each exon both sequenced with the forward and the backward PCR primer. We detected a sequence variation, which was a known polymorphism in exon 5 of RASEF encoding a R262C (C-› T; Arginine -› Cysteine) substitution (Figure 4 .1). This SNP occurs frequently in the population, with reported frequencies between 50% and 58% of the Caucasian population (Sweetser et al., 2005) . In 10 of the 11 cell lines, a homozygous genotype of the T allele was observed. The primary uveal melanomas (n = 35) displayed a normal frequency of the SNP (54%), with 16 uveal melanomas presenting a heterozygous genotype (Table 4. 
Expression analysis
The allelic imbalance observed in the primary uveal melanoma was followed up by RASEF RT-PCR expression analysis. In the cell lines, two groups were distinguishable, based on expression levels. 
Methylation Analysis
Because we did not detect mutations that could explain the low RASEF expression in the primary uveal melanomas and the cell lines, we considered epigenetic regulation as the possible mechanism of downregulation. All five RASEF-expressing cell lines contained an unmethylated promoter while hypermethylation of all CpGs within the amplicon was present in all six cell lines that lacked RASEF expression. The analysis of methylation with melting temperature was confirmed by sequence analysis (Figure 4.3) . In primary uveal melanomas, methylation was much more heterogeneous and never To validate methylation in primary tumors, we used restriction-enzyme analysis. By HinfI digestion, we were able to confirm RASEF methylation in primary uveal melanoma (data not shown). Next, we set out to isolate the methylated fraction and applied PAP. By applying PAP, we were able to show completely methylated alleles and thereby validate melting temperature analysis in five tumors that had shown a methylated fraction in the background of unmethylated DNA. In one sample, a methylated allele was detected in a tumor that had shown a normal curve with melting-temperature analysis, suggesting a very low level of the methylated allele (Figure 4.3) .
Survival
The mean follow-up of the 35 patients was 78 months (2-210 months), and 20 patients had died of tumor-related metastasis at the time of analysis. Two patients had died of a metastasis from another primary tumor (UM7 and UM25), one patient was lost to follow-up (UM22) after 2 months, and two patients had died of unknown causes. The presence of methylation within the RASEF promoter region correlated with death due to metastatic disease (P = 0.024; log rank test). The genotype of the 35 tumors did not correlate to cell type, methylation status, or the development of metastatic disease (P = 0.441;
Although the genotype itself was not associated with metastatic death, patients with a homozygous genotype and methylation of the RASEF gene (n = 7) had a significantly higher risk of development of metastasis than did patients with a heterozygous genotype and no methylation (survival 51 +/-15.5 vs.
161 +/-19.0 months; P = 0.019). 
Chapter 4 Discussion
Linkage analysis in uveal and cutaneous melanoma families identified the 9q21 region as a locus for a potential TSG involved in the development of melanoma. In addition, LOH analysis in two uveal melanomas from members of the families in which linkage was identified indicated 9q21 to be the possible region for a TSG (Jönsson et al., 2005) . The 9q21 region harbors the RASEF gene, which is potentially involved in the RAS pathway prominent in the development of melanoma (Padua et al., 1984; Rimoldi et al., 2003) . As patients with melanoma from the family just mentioned had been analyzed for RASEF mutations, we set out to analyze sporadic uveal melanoma and uveal melanoma cell lines.
In line with the findings of Jönsson et al., (Jönsson et al., 2005) we did not detect any mutations in the RASEF gene other than a known SNP (Jönsson et al., 2005; Sweetser et al., 2005) . Using this SNP, we detected allelic imbalance in some of the tumors that were heterozygous for this marker (UM13 and -21). Because the imbalances were not complete, we suspect tumor heterogeneity in the primary tumors in contrast to the cell lines, all of which, with one exception, displayed a homozygous genotype.
Gene expression analysis revealed that 5 of 11 uveal melanoma cell lines had high RASEF expression, whereas the others hardly showed expression. As almost all the low expression cell lines displayed the homozygous T-allele, there appears to be an association between expression and genotype. This apparent association, however, could also be based on the small number of cell lines that were tested and the fact that three cell lines were derived from the same patient (Mel 270, OMM 2.3, and OMM 2.5).
In the primary tumors, expression varied widely and often exceeded the expression seen in the cell lines.
Among the uveal melanomas with low RASEF expression a homozygous genotype prevailed, but this fact does not favor a specific allele. This finding may indicate that there is no risk factor linked to either allele and that the low expression is more likely due to a somatic alteration. As we had not observed any mutations in the cell lines, we subsequently considered epigenetic modifications as the cause of low RASEF expression. Indeed, all cell lines that did not express RASEF contained a methylated promoter, whereas all cell lines with expression lacked this methylation, confirming our hypothesis. Hereafter, we performed demethylation experiments with 5-azacytidine, which revealed a highly induced expression in a cell line with methylated RASEF. Demethylation of an unmethylated cell line resulted in the opposite effect. The demethylating agent is highly toxic and may explain downregulation of RASEF expression in the unmethylated cell line. Toxicity of 5-azacytidine and demethylation of all the other genes during treatment are the reasons that we reserve functional analysis using genetically modified cell lines for follow-up research. The primary uveal melanomas displayed heterogeneity for RASEF methylation but never reached levels above ~ 50% methylation, and most commonly only a part of the CpGs present in the promoter region was methylated. Furthermore, methylation not only coincided with low expression but also with a homozygous genotype, which suggests a combination of methylation and LOH being the mechanism of loss of expression. The additional effect of LOH seems to be associated with the aggressiveness of the tumor, because homozygous tumors with a methylated RASEF promoter region tended to have a decreased survival compared with heterozygous tumors without methylation (P = 0.019; Figure 4 .4). To confirm the suggested mechanism, we compared the RASEF homozygous genotype of four tumors with the genotype of their peripheral blood leukocytes, also obtained at time of enucleation. One person, in whom the tumor showed a nearly complete homozygous T allele genotype, revealed a heterozygous genotype in leukocyte DNA, confirming the mechanism of LOH in tumor tissue (Figure 4 .5). Of interest, in the tumor tissue of this patient, the RASEF gene was methylated, furthermore confirming our conclusion. We conclude that homozygosity in combination with methylation is the mechanism that targets RASEF in uveal melanoma, appointing RASEF as a bona fide tumor suppressor that is epigenetically silenced in uveal melanoma. Allelic imbalance at this locus supports a tumor-suppressor role for RASEF; however, analysis of RASEF in proliferation, survival, and migration of uveal melanoma is needed to confirm this.
